文献速递产科母胎医学

22q11.2缺失综合征高风险产前筛查结果对产科和新生儿管理的影响:SMART研究的二次分析

Impact of high-risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study.
PubMed 文献 · Prenat Diagn · 2023-12-08

该研究为SMART研究的二次分析,纳入2015至2019年登记的18020名参与者,比较cfDNA筛查22q11.2缺失综合征高风险与低风险人群的产科和新生儿管理差异。结果显示高风险组产前诊断检测率和胎儿超声心动图率更高,未行产前诊断的高风险新生儿遗传学检测及22q11.2DS相关评估率更高,但这些干预未普遍执行,超过50%的高风险婴儿出院时未行遗传学检测。

要点

  • cfDNA筛查22q11.2DS高风险与更高的产前诊断检测(55.3% vs 2.0%)和胎儿超声心动图(76.9% vs 19.6%)相关。
  • 未行产前诊断的高风险新生儿遗传学检测(46.2% vs 0%)、超声心动图(30.8% vs 4.0%)、血钙评估(46.2% vs 4.1%)和淋巴细胞计数(53.8% vs 15.7%)率更高。
  • 超过50%的高风险婴儿出院时未行遗传学检测,可能错失改善结局的机会。

核心结论

  • 22q11.2DS高风险筛查结果与更高的产前和新生儿诊断性遗传学检测及其他22q11.2DS特异性评估率相关,但这些干预未普遍执行,超过50%的高风险婴儿出院时未行遗传学检测,可能错失改善受影响个体结局的机会。

研究设计与样本

  • SMART研究的二次分析,纳入2015至2019年登记的18020名合格参与者,将cfDNA筛查22q11.2DS高风险者与低风险队列比较妊娠特征和产科管理;为评估新生儿护理差异,将未行产前遗传学确认的高风险新生儿与1:1匹配的低风险队列比较。

主要发现

  • 18020名参与者中,38名(0.21%)为cfDNA筛查22q11.2DS高风险,17982名(99.79%)为低风险。
  • 高风险组产前诊断检测率为55.3%(21/38),低风险组为2.0%(352/17982),p < 0.001。
  • 高风险组胎儿超声心动图率为76.9%(10/13),低风险组为19.6%(10/51),p < 0.001。
  • 未行产前诊断的高风险新生儿遗传学检测率为46.2%(6/13),匹配低风险新生儿为0%(0/51),P < 0.001。
  • 未行产前诊断的高风险新生儿超声心动图率为30.8%(4/13),匹配低风险新生儿为4.0%(2/50),p = 0.013。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: One goal of prenatal genetic screening is to optimize perinatal care and improve infant outcomes. We sought to determine whether high-risk cfDNA screening for 22q11.2 deletion syndrome (22q11.2DS) affected prenatal or neonatal management. METHODS: This was a secondary analysis from the SMART study. Patients with high-risk cfDNA results for 22q11.2DS were compared with the low-risk cohort for pregnancy characteristics and obstetrical management. To assess differences in neonatal care, we compared high-risk neonates without prenatal genetic confirmation with a 1:1 matched low-risk cohort. RESULTS: Of 18,020 eligible participants enrolled between 2015 and 2019, 38 (0.21%) were high-risk and 17,982 (99.79%) were low-risk for 22q11.2DS by cfDNA screening. High-risk participants had more prenatal diagnostic testing (55.3%; 21/38 vs. 2.0%; 352/17,982, p < 0.001) and fetal echocardiography (76.9%; 10/13 vs. 19.6%; 10/51, p < 0.001). High-risk newborns without prenatal diagnostic testing had higher rates of neonatal genetic testing (46.2%; 6/13 vs. 0%; 0/51, P < 0.001), echocardiography (30.8%; 4/13 vs. 4.0%; 2/50, p = 0.013), evaluation of calcium levels (46.2%; 6/13 vs. 4.1%; 2/49, P < 0.001) and lymphocyte count (53.8%; 7/13 vs. 15.7%; 8/51, p = 0.008). CONCLUSIONS: High-risk screening results for 22q11.2DS were associated with higher rates of prenatal and neonatal diagnostic genetic testing and other 22q11.2DS-specific evaluations. However, these interventions were not universally performed, and >50% of high-risk infants were discharged without genetic testing, representing possible missed opportunities to improve outcomes for affected individuals.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Martin K, Norton ME, MacPherson C, et al. Impact of high-risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenat Diagn. 2023. PMID: 38066724. doi:10.1002/pd.6483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。